Nucleic acids as therapeutics

From Nucleic Acids Sequences to Molecular Medicine

Volumn , Issue , 2012, Pages 19-45

  Pushpendra, Saraswat ^a   Arvind, Pareek ^b   Anil, Bhandari ^c  

^a MAHATMA GANDHI UNIVERSITY   (India)

^b Mahatma Gandhi Institute of Applied Sciences   (India)

^c Jodhpur National University   (India)

Author keywords

DNA based therapeutics; Gene therapy; Gene transfer technology; Liposomes; Nonviral vectors; Nucleic acid therapeutics; RNA based therapeutics; Viral vectors

Indexed keywords

EID: 85029166583     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-27426-8_2     Document Type: Chapter

References (237)

1. Agarawal S, Tang JY (1992) GEM-91-an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 2:261-266
2. Agarwal S, Kandimalla ER (2000) Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today 6:72-81
3. Aigner A, Juhl H, Malerczyk C et al (2001) Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumor cell proliferation. Oncogene 20:2101-2111
4. Akhtar S, Hughes MD, Khan A (2000) The delivery of antisense therapeutics. Adv Drug Deliv Rev 44:3-21
5. Albert MM, Francesca S, Aric AP et al (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240-2248
6. Alt M, Ring R, Hofschneider PH et al (1995) Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707-717
7. Alvarez RD, Barns MN, Gomez-Navarro J (2000a) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res 6:3081-3087
8. Alvarez RD, Gomez-Navarro J, Wang M (2000b) Adenoviral mediated suicide gene therapy for ovarian cancer. Mol Ther 2:524-530
9. Anderson WF (1992) Human gene therapy. Science 256:808-813
10. Anderson WF (1998) Human gene therapy. Nature (Lond) 392:25-30
11. Anil A (2003) Undercover genes slip into the brain. http://www.newscientist.com/section/science- news/. 22 Mar 2003
12. Audouy S, Molema G, De Leij L et al (2000) Serum as a modulator of lipoplex-mediated gene transfection: dependence of amphiphile cell type and complex stability. J Gene Med 2:465-476
13. Azad RF, Driver VB, Tanaka K et al (1993) Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 37:1945-1954
14. Baekelandt V, De Strooper B, Nuttin B et al (2000) Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol 2:540-554
15. Baker BF (2001) The role of antisense oligonucleotides in the wave of genomic information. Nucleosides Nucleotides Nucleic Acids 20:397-399
16. Baltimore DP (1988) Intracellular immunization. Nature 335:395-397
17. Beelman CA, Parker R (1995) Degradation of mRNA in eukaryotes. Cell 81:179-183
18. Ben H (2007) Doctors test gene therapy to treat blindness. http://www.reuters.com/article/scienceNews/idUSL016653620070501?/. 1 May 2007
19. Bernstein E, Caudy AA, Hammond SM et al (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366
20. Bertrand JR, Pottier M, Vekris A et al (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296:1000-1004
21. Bett AJ, Prevec L, Graham FL (1993) Packaging capacity, and stability of human adenovirus type 5 vectors. J Virol 67:5911-5921
22. Bob H (2003) Gene therapy may switch off Huntington’s. http://www.newscientist.com/section/science-news/. 13 Mar 2003
23. Borchard G (2001) Chitosans for gene delivery. Adv Drug Deliv Rev 52:145-150
24. Bordier B, Helena C, Barr PJ et al (1992) In vitro effects of antisense oligonucleotides on human immunodeficiency virus type 1 reverses transcription. Nucleic Acids Res 20:1999-2006
25. Bordignon C, Notarangilo LD, Nobili N (1995) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-475
26. Boussif O, Lezoualc’h F, Zanta MA (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimin. Proc Natl Acad Sci USA 92:7297-7301
27. Breaker RR, Joyce GF (1994) DNA enzyme that cleaves RNA. Trends Biotechnol 1:223-229
28. Bunnel BA, Morgan RA (1996) Gene therapy for HIV infection. Drugs Today 32:09-224
29. Burke JM (1996) Hairpin ribozyme: current status and future prospects. Biochem Soc Trans 24:608-615
30. Byrnes AP, Rusby JE, Wood MJ (1995) Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66:1015-1024
31. Campagno D, Lampe JN, Bourget C et al (1999) Antisense oligonucleotides containing modified bases inhibit in vitro translation of Leishmania amazonensis mRNAs by invading the miniexon hairpin. J Biol Chem 274:8191-8198
32. Caplen NJ (2004) Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 11:1241-1248
33. Caplen NJ, Alton EW, Middleton PG (1995) Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1:39-46
34. Carpenter DE, Stevens JG (1996) Long term expression of a foreign gene from a unique position in the latent herpes simplex virus genome. Hum Gene Ther 7:1447-1454
35. Chaloin L, Lehmann MJ, Sczakiel G et al (2002) Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 30:4001-4008
36. Chamberlain JS (2002) Gene therapy of muscular dystrophy. Hum Mol Genet 11:2355-2362
37. Clemens PR, Kochanek S, Sunada Y (1996) In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 3:965-972
38. Compton SH, Mecklenbeck S, Mejia JE (2000) Stable integration of large (>100 kb) PAC constructs in HaCa T keratinocytes using an integrin-targeting peptide delivery system. Gene Ther 7:1600-1607
39. Cone RD, Mulligan RC (1984) High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci USA 81:6349-6353
40. Cowsert LM, Fox MC, Zon G et al (1993) In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for the genital warts. Antimicrob Agents Chemother 37:171-177
41. Crooke ST (1998a) An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 8:115-122
42. Crooke ST (1998b) Vitravene another piece in the mosaic. Antisense Nucleic Acid Drug Dev 8:vii-v3
43. Crooke ST (1999a) Molecular mechanisms of antisense drugs. Biochem Biophys Acta 1489:31-43
44. Crooke ST (1999b) Molecular mechanisms of antisense drugs: human RNaseH. Antisense Nucleic Acid Drug Dev 9:377-379
45. Danny P (2002) Subtle gene therapy tackles blood disorder. http://www.newscientist.com/section/science-news/. 11 Oct 2002
46. de Saultrait VR, Lozach P-Y, Altmeyer R et al (2002) DNAaptamers derived from HIV-1 RNaseH inhibitors are strong anti-integrase agents. J Mol Biol 324:195-203
47. Dean NM, McKay R, Condon TP et al (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intracellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269:16416-16424
48. Denli AM, Tops BBJ, Plasterk RHA et al (2004) Processing of primary microRNAs by the microprocessor complex. Nature 432:231-235
49. Dokka S, Toledo D, Shi X et al (2000) Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17:521-525
50. Dong JY, Fang PD, Frizzel RA (1996) Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7:2101-2112
51. Dorsett Y, Tuschl T (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3:318-329
52. Dunbar CE, Kohn DB, Shiffman R (1998) Retroviral transfer of the glucoceribrosidase gene into CD34+ cells from patients with Goucher disease: in vivo detection of transduced cells without myeloblation. Hum Gen Ther 9:2629-2640
53. Eamshaw DJ, Gait MJ (1997) Progress toward the structure and therapeutic use of the hairpin ribozyme. Antisense Nucleic Acid Drug Dev 7:403-411
54. Ehsan A, Mann MJ, Dell’Acqua G et al (2001) Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121:714-722
55. Ellison KE, Bisphoric NH, Webster KA (1996) Fusigenic liposome-mediated DNA transfer into cardiac myocytes. J Mol Cell Cardiol 28:1385-1399
56. Emma Y (2002) ‘Miracle’ gene therapy trial halted. http://www.newscientist.com/section/science-news/. 3 Oct 2002
57. Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-152
58. Fattal E, Dellattre J, Dubernet C et al (1999) Liposomes for the delivery of nucleotides and oligonucleotides. STP Pharma Sci 9:383-390
59. Fattal E, Dubernet C, Couvrur P (2001) Liposome-based formulations for the delivery of oligonucleotids. STP Pharma Sci 11:31-44
60. Felgner PL, Gadek TR, Holm M (1987) Lipofection: a highly efficient, lipid-mediated DNA- transfection procedure. Proc Natl Acad Sci USA 84:7413-7417
61. Felgner JH, Kumar R, Sridhar CN (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269:2550-2561
62. Filion MC, Philips NC (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345-356
63. Fillion P, Desjardins A, Sayasith K et al (2001) Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid-liposome encapsulated antisense oligonucleotides. Biochim Biophys Acta 1515:44-54
64. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391:806-811
65. Fisher KJ, Jooss K, Alston J (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3:306-312
66. Freimark BD, Blzinger HP, Florack VJ (1998) Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 160:4580-4586
67. Fujji S, Huang S, Fong TC (2000) Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther 7:1220-1230
68. Fynan EF, Webster RG, Fuller DH (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90:11478-11482
69. Galanis E, Russell S (2001) Cancer gene therapy clinical trials: lessons for the future. Br J Cancer 85:1432-1436
70. Garton KJ, Ferri N, Raines EW (2002) Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. Biotechniques 32:830-843
71. Ge Q, McManus MT, Nguyen T et al (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 100:2718-2723
72. Gerviax A, Li X, Kraus G et al (1997) Multigene antivirus vectors inhibit divers human immunodeficiency virus type 1 clades. J Virol 71:3048-3053
73. Gewirtz AM, Sokol DL, Ratajczak MZ (1998) Nucleic acid therapeutics: state of the art and future prospects. Blood 92:712-736
74. Godbey WT, Mikos AG (2001) Recent progress in gene delivery using non-viral transfer complexes. J Control Release 72:115-125
75. Guo W, Gosselin MA, Lee RJ (2002) Characterization of a novel diolein-based LPD II vector for gene delivery. J Control Release 83:121-132
76. Hale SJ, Green NK (2002) Viral approaches to cancer gene therapy. Expert Opin Therapeut Patents 12:369-378
77. Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286:950-952
78. Hammond SM (2005) Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 579:5822-5829
79. Hammond SM, Bernstein E, Beach D et al (2000) An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature 404:293-296
80. Hampel A (1998) The hairpin ribozyme: discovery, two dimensional model, and development for gene therapy. Prog Nucleic Acid Res Mol Biol 58:1-39
81. Han J, Lee Y, Yeom K-H et al (2004) The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18:3016-3027
82. Hanecak R, Brown-Driver V, Fox MC et al (1996) Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 70:5203-5212
83. Heider H, Verca HB, Rusconi S et al (2000) Comparison of lipid-mediated, and adenoviral gene transfer in human monocyte-derived macrophages and COS-7 cells. Biotechniques 28:260-270
84. Hermonat PL, Quirk JG, Bishop BM (1997) The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett 407:78-84
85. Hofland HEJ, Shephard L, Sullivan SM (1996) Formation of stable cationic lipid/DNA complexes for gene transfer. Proc Natl Acad Sci USA 93:7305-7309
86. Horner AA, van Uden JH, Jubeldia JM et al (2001) DNA-based immunotherapeutics for the treatment of allergic disease. Immunol Rev 179:102-118
87. Huang L, Viroonchatapan E (1999) Introduction. In: Huang L, Huang M-C, Wagner E (eds) Nonviral vectors for gene therapy. Academic Press, San Diego, CA, pp 3-22
88. Hwang SJ, Davis ME (2001) Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr Opin Mol Ther 3:183-191
89. Hyde SC, Southern KW, Gileadi U (2000) Repeat administration of DNA/liposome to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7:1156-1165
90. Jackson AL, Linsley PS (2004) Noise amidst the silence: off-target effects of siRNAs? Trends Genet 20:521-524
91. James WB, Alexander JS, Susie SB et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231-2239
92. Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45:1628-1650
93. Jenkins RG, Herrick SE, Meng QH (2000) An integrin-targeted non-viral vector for pulmonary gene therapy. Gene Ther 7:393-400
94. Jennifer FW (2002) Murine gene therapy corrects symptoms of sickle cell disease. Scientist 16:36. http://www.the-scientist.com/2002/3/18
95. Johnston SA, Talaat AM, McGuire MG (2002) Genetic immunization what’s in a name? Arch Med Res 33:325-329
96. Jooss K, Yang Y, Fisher KJ (1998) Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72:4212-4223
97. Kamiya H, Tsuchiya H, Yamazaki J et al (2001) Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv Drug Deliv Rev 52:153-164
98. Kang S-H, Zirbes EL, Kole R (1999) Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents. Antisense Nucleic Acid Drug Dev 9:497-505
99. Katz SM, Tian L, Stepkowski SM et al (1997) Effect of ICAM-1/LFA-1 blockade on pancreatic islet allograft survival function, and early cytokine production. Transplant Proc. 29(1-2):748-749
100. Kaur G, Roy I (2008) Therapeutic applications of aptamers. Expert Opin Investig Drugs 17:43-60
101. Kaushik S, Namgung R, Kim WJ (2011) Polymers in small-interfering RNA delivery. Nucleic Acid Ther 21:133-147
102. Khaw BA, da Silva J, Vural I et al (2001) Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release 75:199-210
103. Kim SH, Yu SS, Park JS et al (1998) Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 72:994-1004
104. Kinchington D, Galpin S, Jeroszewski J et al (1992) A comparison of gag, pol, and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antiviral Res 17:53-62
105. Kochanek S, Clemens PR, Mitani K (1996) A new adenoviral vector: replacement of viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta- galactosidase. Proc Natl Acad Sci USA 93:5731-5736
106. Kotin RM, Siniscalco M, Samulski RJ (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87:2211-2215
107. Krauss WC, Park JW, Kirpotin DB et al (2000) Emerging antibody-based HER2 (ErbB-2/new) therapeutics. Breast Dis 11:113-124
108. Kukowska-Latello JF, Bielinska AU, Johnson J (1996) Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 93:4897-4902
109. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628-1644
110. Lakkaraju A, Dubinsky JM, Low WC et al (2001) Neurons are protected from excitotoxic death by p53 antisense oligonuclotides delivered in anionic liposomes. J Biol Chem 276:32000-32007
111. Lappalainen K, Jaaskelainen I, Syrjanen K et al (1994) Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 11:1127-1131
112. Lee RJ, Huang L (1997) Lipidic vector systems for gene transfer. Crit Rev Ther Drug Carrier Syst 14:173-206
113. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854
114. Lee H, Williams SKR, Allison SD et al (2001) Analysis of self-assembled cationic lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering. Anal Chem 73:837-8343
115. Lee Y, Kim M, Han J et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23:4051-4060
116. Legendre JY, Szoka FC Jr (1992) Delivery of plasmid DNA into mammalian cell lines using pH- sensitive liposomes: comparison with cationic liposomes. Pharm Res 9:1235-1242
117. LeHoux JG, Grondin F (1993) Some effects of chitosan on liver function in the rat. Endocrinology 132:1078-1084
118. Lehrman S (1999) Virus treatment questioned after gene therapy death. Nature 401:517-518
119. Lemkine GF, Demeneix BA (2001) Polyethylenimins for in vivo gene delivery. Curr Opin Mol Ther 3:178-182
120. Lever AML (1996) Gene therapy in the fight against AIDS. Expert Opin Ther Pat 6:161-167
121. Lewis PF, Emerman M (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510-516
122. Liebhaber SA (1997) mRNA stability and the control of gene expression. Nucleic Acids Symp Ser 36:29-32
123. Lien Y-HH, Lie L-W (2002) Gene therapy for renal disorders: what are the benefits for the elderly? Drugs Aging 19:553-560
124. Lisziewicz J, Sun D, Klotman M et al (1992) Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci USA 89:11209-11213
125. Lisziewicz J, Sun D, Metelev V et al (1993) Long term treatment of human immunodeficiency virus infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA 90:3860-3864
126. Liu F, Qi H, Huang L et al (1997) Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther 4:517-523
127. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258-1266
128. Lollo CP, Banaszczyk MG, Mullen PM (2002) Poly-L-lysine based gene delivery systems: synthesis, purification, and application. Methods Mol Med 69:1-13
129. Lotze MT, Kost TA (2002) Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther 9:692-699
130. Lowenstein PR, Morrison EE, Bain D (1994) Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in post mitotic-polarized cortical neurons and glial cells in vitro. Neuroscience 60:1059-1077
131. Lund E, Guttinger S, Calado A et al (2004) Nuclear export of microRNA precursors. Science 30:95-98
132. Luo D, Saltzman WM (2000) Synthetic DNA delivery systems. Nat Biotechnol 18:33-37
133. Maclean AL, Symonds G, Ward R (1997) Immunoliposomes as targeted delivery vehicles for cancer therapeutics. Int J Oncol 11:325-332
134. Macpherson JL, Fly JA, Sun LO et al (1999) Ribozymes in gene therapy of HIV-1. Front Biosci 4:D497-D505
135. Mah C, Byrne BJ, Flotte TR (2002) Virus-based gene delivery systems. Clin Pharmacokinet 41:901-911
136. Mann R, Mulligan RC, Baltimore D (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159
137. Mann MJ, Gibbons GH, Hutchinson H (1999a) Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA 96:6411-6416
138. Mann MJ, Whittemore AD, Donaldson MC et al (1999b) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354:1493-1498
139. Marciniak RA, Garcia-Blanco MA, Sharp PA (1990) Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc Natl Acad Sci USA 87:3624-3638
140. Mardan T, Kopecek J, Kissel T (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54:715-758
141. Marshal J, Yew NS, Eastman SJ et al (1999) Cationic lipid-mediated gene delivery to the airways. In: Wagner E (ed) Nonviral vectors for gene therapy. Academic Press, pp 39-68
142. Martin KR, Klein RL, Quigley HA (2002) Gene delivery to the eye using adeno-associated viral vectors. Methods 28:267-275
143. Martinez MA, Gutierrez A, Armond-Ugon M et al (2002) Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16:2385-2390
144. McAlister DV, Allen MG, Prausnitz MR (2000) Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2:289-313
145. McMinus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3:737-747
146. McTaggart S, Al-Rubeai M (2002) Retroviral vectors for human gene delivery. Biotechnol Adv 20:1-31
147. Michou AI, Santoro L, Christ M (1997) Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther 4:473-482
148. Mirabelli CK, Bennet CF, Anderson K et al (1991) In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Des 6:647-661
149. Mizuno T, Chou MY, Inouye M (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci USA 81:1966-1970
150. Mizutani TN, Kato M, Hirota K et al (1995) Inhibition of hepatitis C virus replication by antisense oligonucleotids in culture cells. Biochem Biophys Res Commun 212:906-911
151. Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients mediated by transfer of genetically engineered lymphocytes. Science 314:126-129. http://www.cancer.gov/newscenter/pressreleases/MelanomaGeneTherapy/. 31 Aug 2006
152. Morsy MA, Gu M, Motzel S (1998) An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95:7866-78671
153. Morvan F, Porumb H, Degols G et al (1993) Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem 36:280-287
154. Mulherkar R (2001) Gene therapy for cancer. Curr Sci 81:555-560
155. Mumper RJ, Wang J, Klakamp SL (1998) Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. J Control Release 52:191-203
156. Nabel GJ, Nabel EG, Yang ZY (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biological activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311
157. Nabel GJ, Gordon D, Bishop DK (1996) Immune response in human melanoma after transfer of an allogenic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93:15388-15393
158. Nakamura M, Devila-Zavala P, Tokuda H (1998) Uptake and gene expression of naked plasmid DNA in cultured brain microvessel endothelial cells. Biochem Biophys Res Commun 245:235-239
159. Naldini L, Blomer U, Gally P (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267
160. Naughton BA, Dai Y, Sibanda B (1992) Long-term expression of a retrovirally introduced beta- galactosidase gene in rodent cells implanted in vivo using biodegradable polymer meshes. Somat Cell Mol Genet 18:451-462
161. Neumann E, Schaefer-Ridder M, Wang Y (1982) Gene transfer into lyoma by electroporation in high electric fields. EMBO J 1:841-845
162. Noone PG, Hohnker KW, Zhou Z (2000) Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 1:105-114
163. Nyberg-Hoffman C, Aguilar-Cardova E (1999) Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med 5:955-957
164. Onodera M, Ariga T, Kawamura N (1998) Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immunodeficiency caused by adenosine deaminase deficiency. Blood 91:30-36
165. Otsu M, Candotti F (2002) Gene therapy in infants with severe combined immunodeficiency. BioDrugs 16:229-239
166. Owens RA (2002) Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVS 1. Curr Gene Ther 2:145-159
167. Parks RJ, Grahm FL (1997) A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 71:3293-3298
168. Patil SD, Burgess DJ (2003) DNA-based pharmaceuticals: therapeutics for the 21st century. AAPS Newsmagazine 6:27
169. Patil SD, Rhodes DG (2000a) Conformation of oligodeoxynucleotides associated with anionic liposomes. Nucleic Acids Res 28:4125-4129
170. Patil SD, Rhodes DG (2000b) Influence of divalent cations on the conformation of phosphor- othioate oligodeoxynucleotides: a circular dichroism study. Nucleic Acids Res 28:2439-2445
171. Patil SD, Rhodes DG, Burgess DJ (2004) Anionic liposomal delivery system for DNA transfection. AAPS J 6:E29
172. Patil SD, Rhodes DG, Burgess DJ (2005) Biophysical characterization of anionic lipoplexes. Biochim Biophys Acta—Biomembranes 7:E61-E77
173. Pedroso de Lima MC, Simoes S, Pires P et al (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev 47:277-294
174. Perrie Y, Gregoriadis G (2000) Liposome-entrapped plasmid DNA: characterization studies. Biochim Biophys Acta 1475:125-132
175. Reddy JA, Low PS (2000) Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 64:27-37
176. Regnier V, Tahiri A, Andre N et al (2000) Electroporation-mediated delivery of 3’-protected phosphodiester oligodeoxynucleotides to the skin. J Control Release 67:337-346
177. Report (1995) The United Kingdom Health Minister’s Gene Therapy Advisory Committee. Guidance on making proposals to conduct gene therapy research on human subjects. Hum Gene Ther 6:335-346
178. Rizzuto G, Cappelletti M, Maione D (1999) Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 96:6417-6422
179. Roe T, Reynolds TC, Yu G et al (1993) Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099-2108
180. Rols MP, Delteil C, Golzio M (1998) In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 16:168-171
181. Rose JA, Berns KI, Hoggan MD (1969) Evidence for a single stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci USA 64:863-869
182. Rosenberg SA, Blaese RM, Branner MK et al (2000) Human gene marker/therapy protocols. Hum Gene Ther 11:919-979
183. Ruvkun G (2001) Molecular biology: glimpses of a tiny RNA world. Science 294:797-799
184. Samulski RJ, Chang LS, Shenk T (1989) Helper-stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63:3822-3828
185. Samulski RJ, Zhu X, Xiao X (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941-3950
186. Scanlon KJ, Ohta Y, Ishida H et al (1995) Oligonucleotide—mediated modulation of mammalian gene expression. FASEB J 9:1288-1296
187. Schatzlein A (2009) Nano-treatment to torpedo cancer. http://news.bbc.co.uk/2/hi/health/7935592.stm/. 10 Mar 2009
188. Scherr M, Morgan MA, Eder M (2003) Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem 10:245-256
189. Schiedner G, Morral N, Parks RJ (1998) Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18:180-183
190. Scott M (2007) Dual gene therapy suppresses lung cancer in preclinical test. http://www.newswise.com/p/articles/view/526526/. 11 Jan 2007
191. Shankar P, Manjunath N, Lieberman J (2005) The prospect of silencing disease using RNA interference. J Am Med Assoc 293:1367-1373
192. Sheridan PL, Bodner M, Lynn A (2000) Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. Mol Ther 2:262-275
193. Shi N, Zhang Y, Zhu C et al (2001) Brain-specific expression of an exogenous gene after IV administration. Proc Natl Acad Sci USA 98:12754-12759
194. Shinmura K, Morishita R, Aoki M (2000) Catheter-delivered in vivo gene transfer into rat myocardium using the fusigenic liposomal mediated method. Jpn Heart J 41:633-647
195. Simoes S, Slepushkin V, Gaspar R (1998) Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther 5:955-964
196. Simons RW, Kleckner N (1983) Translational control of IS10 transposition. Cell 34:683-691
197. Singh M, Briones M, Ott G (2000) Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 97:811-816
198. SoRelle R (2000) Who owns your DNA? Who will own it? Circulation 101:e67-e68
199. Speedie M (2005) Antisense therapeutic agents. In: Williams DA, Lemke TL (eds) Foye’s principles of medicinal chemistry, 5th edn. Lippincott, Philadelphia, PA
200. Stein CA (1998) How to design an antisense oligodeoxynucleotides experiment: a consensus approach. Antisense Nucleic Acid Drug Dev 8:129-132
201. Stewart AK, Lassam NJ, Quirt IC (1999) Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6:350-363
202. Stull RA, Szoka FC Jr (1995) Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res 12:463-465
203. Sullenger BA, Cech TR (1993) Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262:1566-1569
204. Sullenger BA, Gallardo HF, Ungers GE et al (1990) Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608
205. Sullenger BA, Gallardo HF, Ungers GE et al (1991) Analysis of trans-acting response decoy RNA- mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 65:6811-6816
206. Sviridov YV, Zhadanov RI, Podobed OV et al (2001) The LacZ gene transfer into L929 cells and [14 C]-DNA tissue distribution following intraperitoneal administration of new pH-sensitive lipoplexes in mice. Cytobios 106:7-14
207. Sylvia PW (2002) DNA nanoballs boost gene therapy. http://www.newscientist.com/section/science-news/. 12 May 2002
208. Tait DL, Obermiller PS, Hatmaker AR (1999) Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res 5:1708-1714
209. Tang MX, Szoka FC (1997) The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 4:823-832
210. Tejada-Berges T, Granai CO, Gordinier M et al (2002) Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2:143-150
211. Tonkinson JL, Stein CA (1993) Antisense nucleic acids-prospects for antiviral intervention. Antiviral Chem Chemother 4:193-199
212. Tuschl T, Zamore PD, Lehmann R et al (1999) Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13:3191-3197
213. Uherek C, Wels W (2000) DNA-carrier proteins for targeted gene delivery. Adv Drug Deliv Rev 44:153-166
214. Usman N, Beigelman L, McSwiggen JA (1996) Hammerhead ribozyme engineering. Curr Opin Struct Biol 1:527-533
215. Van Ginkel FW, Mc Ghee JR, Liu C (1997) Adenoviral gene delivery elicits distinct pulmonary- associated T helper cell responses to the vector and to its transgene. J Immunol 159:685-693
216. Van Ommen GJB, Bakker E, Den Dunnen JT (1999) The human genome project and the future of diagnostics, treatment, and prevention. Lancet 354:5-10
217. Venugopalan P, Jain S, Sankar S et al (2002) pH sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazai 57:659-671
218. Vorburger SA, Hunt KK (2002) Adenoviral gene therapy. Oncologist 7:46-59
219. Wadhwa MS, Knoell DL, Young AP (1995) Targeted gene delivery with a low molecular weight glycopeptide carrier. Bioconjug Chem 6:283-291
220. Walther W, Stein U (2000) Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60:249-271
221. Welch PJ, Yei S, Barber JR (1998) Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 10:163-171
222. Wheeler CJ, Felgner PL, Tsai YJ (1996) A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci USA 93:11454-11459
223. Wolf JK, Jenkins AD (2002) Gene therapy for ovarian cancer. Int J Oncol 21:461-468
224. Wolff JA, Malone RW, Williams P (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468
225. Wong IH (2001) Methylation profiling of human cancers in blood: molecular monitoring and prognostication. Int J Oncol 19:1319-1324
226. Wong TK, Neumann E (1982) Electric field mediated gene transfer. Biochem Biophys Res Commun 107:584-587
227. Xu L, Huang C-C, Huang W (2002) Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1:337-346
228. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L et al (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 114:1133-1142
229. Yang Y, Jooss KU, Su Q (1996a) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3:137-144
230. Yang Y, Su Q, Wilson JM (1996b) Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 70:7209-7212
231. Yi R, YiQ IGM et al (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17:3011-3016
232. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotides. Proc Natl Acad Sci USA 75:280-284
233. Zamore PD, Aronin N (2003) siRNAs knock down hepatitis. Nat Med 9:266-267
234. Zhang L, Gasper WA, Stass SA et al (2002) Angiogenic inhibition mediated by a DNAzyme that target vascular endothelial growth factor receptor 2. Cancer Res 62:5463-5469
235. Zhao W, Kobayashi M, Hosokawa M et al (2002) Adenoviral vectors for cancer gene therapy. Curr Genomics 3:163-180
236. Zhaohui P (2003) China OKs gene therapy drug. Genetic Engineering News 6. http://www.p53therapy.com/news/.19 Nov 2003
237. Zu Putlitz J, Yu Q, Burke JM et al (1999) Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol 73:5381-5387